JAPAN MARKET ENTRY STRATEGY
Japan Market Entry
Strategy for Global
Biotech & Medtech
We help biotech and medtech companies build strategic pathways between global and Japan markets — from Japan entry and KOL engagement to RWE generation and international collaboration.
INTRODUCTION
Entering the Japan market is one of the most complex challenges for global healthcare companies.
Clinical expectations, Regulatory requirements, and stakeholder dynamics are fundamentally different from the US and Europe. Without the right strategy, companies face increased risks, delayed approvals, and failed market entry.
By integrating KOL engagement, strategic clinical design, and Real-World Evidence (RWE), we transform uncertainty into actionable pathways — enabling faster decisions, lower costs, and stronger asset positioning.
CASE STUDIES
Discover how MSC has helped global companies successfully enter and expand in the Japan market.
Our case studies highlight real-world outcomes, including:
Efficient Japan market entry with lean operational design
Strong KOL engagement
Accelerated market adoption by RWE
See how strategy translates into measurable impact.
View DetailsAbout MSC
Satoshi Sugawa, PhD
Scientific Expertise. Strategic Insight. Proven Results.
Satoshi Sugawa, PhD combines deep scientific expertise with extensive healthcare industry leadership to help organizations navigate the Japanese healthcare landscape.
See how strategy translates into measurable impact.
14+
years of Medical Affairs leadership
55+
Real World Evidence studies
400+
clinician and healthcare stakeholder network
40+
scientific publications
25+
academic partnerships across Japan
INSIGHTS
How Overseas Biotech Companies Successfully Enter Japan
1. Executive Summary Japan represents one of the most attractive yet complex pharmaceutical markets globally. As the third-largest pharmaceutical market, it offers strong reimbursement systems, a well-structured healthcare infrastructure, and significant demand driven by an aging population. However, successful market
Read more...KOL Engagement Framework
Strategic Approaches for Overseas Biotech and Pharmaceutical Companies Entering Japan 1. Executive Summary Key Opinion Leaders (KOLs) play a critical role in pharmaceutical and biotech strategy, particularly in Japan where clinical practice patterns, academic influence, and guideline development are tightly
Read more...Typical Failure Patterns in Entering the Japanese Pharmaceutical Market
1. Approval-Centric Thinking – Case: Biotech for a rare disease drug Case: A rare disease drug (analogous to Ultragenyx-type assets) received PMDA approval.Expected price (global benchmark): JPY 120M/yearActual NHI price: JPY 70M/year (~-40%)Sales forecast: JPY 10B → Actual: JPY 5–6BRoot
Read more...